OSE-127
ose immunotherapeutics
['leukemia', 'oseimmuno']
we are pleased to share the latest preclinical efficacy data for ose-127, an anti-il-7 receptor antagonist for the treatment of acute lymphoblastic leukemia (all). the data was presented at the 2022 annual meeting. 
focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immune-oncology and auto-immune diseases.